{
    "2019-10-03": [
        [
            {
                "time": "2023-10-10",
                "original_text": "Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates",
                "features": {
                    "keywords": [
                        "Pharma Stocks",
                        "Third-Quarter Estimates",
                        "Notable"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "10 Insider Trading Stocks: What Execs and Directors Are Buying",
                "features": {
                    "keywords": [
                        "Insider Trading",
                        "Execs",
                        "Directors",
                        "Buying"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "Novartis Reports Additional Data on Spondylitis Drug Cosentyx",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Spondylitis",
                        "Drug",
                        "Cosentyx"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "5 Dividend Aristocrats to Buy as October Sees a Shaky Start",
                "features": {
                    "keywords": [
                        "Dividend Aristocrats",
                        "Shaky Start",
                        "October"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "dividends"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}